163 related articles for article (PubMed ID: 35074904)
1. Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary.
Tarhini AA; Lee SJ; Tan AC; El Naqa IM; Stephen Hodi F; Butterfield LH; LaFramboise WA; Storkus WJ; Karunamurthy AD; Conejo-Garcia JR; Hwu P; Streicher H; Sondak VK; Kirkwood JM
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35074904
[TBL] [Abstract][Full Text] [Related]
2. Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males.
Saad M; Lee SJ; Tan AC; El Naqa IM; Hodi FS; Butterfield LH; LaFramboise WA; Storkus W; Karunamurthy AD; Conejo-Garcia J; Hwu P; Streicher H; Sondak VK; Kirkwood JM; Tarhini AA
J Transl Med; 2022 Jun; 20(1):253. PubMed ID: 35659704
[TBL] [Abstract][Full Text] [Related]
3. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma.
Lee CC; Faries MB; Wanek LA; Morton DL
J Clin Oncol; 2008 Feb; 26(4):535-41. PubMed ID: 18235114
[TBL] [Abstract][Full Text] [Related]
4. Survival and therapeutic response in patients with melanoma of unknown and known primary: a single-centre retrospective analysis.
Ludwig SV; F Cheng P; Mangana J; Braun R; Dummer R; Koelblinger P
Eur J Dermatol; 2020 Dec; 30(6):699-709. PubMed ID: 33459260
[TBL] [Abstract][Full Text] [Related]
5. Improved survival for stage IV melanoma from an unknown primary site.
Lee CC; Faries MB; Wanek LA; Morton DL
J Clin Oncol; 2009 Jul; 27(21):3489-95. PubMed ID: 19451446
[TBL] [Abstract][Full Text] [Related]
6. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
Tarhini AA; Kang N; Lee SJ; Hodi FS; Cohen GI; Hamid O; Hutchins LF; Sosman JA; Kluger HM; Eroglu Z; Koon HB; Lawrence DP; Kendra KL; Minor DR; Lee CB; Albertini MR; Flaherty LE; Petrella TM; Streicher H; Sondak VK; Kirkwood JM
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963015
[TBL] [Abstract][Full Text] [Related]
7. Melanoma patients with an unknown primary tumor site have a better outcome than those with a known primary following therapeutic lymph node dissection for macroscopic (clinically palpable) nodal disease.
van der Ploeg AP; Haydu LE; Spillane AJ; Scolyer RA; Quinn MJ; Saw RP; Shannon KF; Stretch JR; Thompson JF
Ann Surg Oncol; 2014 Sep; 21(9):3108-16. PubMed ID: 24802907
[TBL] [Abstract][Full Text] [Related]
8. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
Tarhini AA; Lee SJ; Hodi FS; Rao UNM; Cohen GI; Hamid O; Hutchins LF; Sosman JA; Kluger HM; Eroglu Z; Koon HB; Lawrence DP; Kendra KL; Minor DR; Lee CB; Albertini MR; Flaherty LE; Petrella TM; Streicher H; Sondak VK; Kirkwood JM
J Clin Oncol; 2020 Feb; 38(6):567-575. PubMed ID: 31880964
[TBL] [Abstract][Full Text] [Related]
9. Survival after lymphadenectomy of nodal metastases from melanoma of unknown primary site.
Gullestad HP; Ryder T; Goscinski M
J Plast Surg Hand Surg; 2023; 57(1-6):109-114. PubMed ID: 34878354
[TBL] [Abstract][Full Text] [Related]
10. Melanoma of unknown primary origin: a population-based study in the Netherlands.
de Waal AC; Aben KK; van Rossum MM; Kiemeney LA
Eur J Cancer; 2013 Feb; 49(3):676-83. PubMed ID: 23031553
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy.
Verver D; Grünhagen DJ; van Akkooi ACJ; Aarts MJB; van den Berkmortel FWPJ; van den Eertwegh AJM; de Groot JWB; Boers-Sonderen MJ; Haanen JBAG; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Tije AJT; Vreugdenhil G; Verhoef C; van der Veldt AAM
Cancer Immunol Immunother; 2021 Nov; 70(11):3123-3135. PubMed ID: 33774697
[TBL] [Abstract][Full Text] [Related]
12. Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies.
Bae JM; Choi YY; Kim DS; Lee JH; Jang HS; Lee JH; Kim H; Oh BH; Roh MR; Nam KA; Chung KY
J Am Acad Dermatol; 2015 Jan; 72(1):59-70. PubMed ID: 25440435
[TBL] [Abstract][Full Text] [Related]
13. Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site.
Prens SP; van der Ploeg AP; van Akkooi AC; van Montfort CA; van Geel AN; de Wilt JH; Eggermont AM; Verhoef C
Ann Surg Oncol; 2011 Dec; 18(13):3586-92. PubMed ID: 21611857
[TBL] [Abstract][Full Text] [Related]
14. Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature.
Utter K; Goldman C; Weiss SA; Shapiro RL; Berman RS; Wilson MA; Pavlick AC; Osman I
Oncology; 2017; 93(4):249-258. PubMed ID: 28746931
[TBL] [Abstract][Full Text] [Related]
15. Stage IV melanoma of unknown primary: A population-based study in the United States from 1973 to 2014.
Scott JF; Conic RZ; Thompson CL; Gerstenblith MR; Bordeaux JS
J Am Acad Dermatol; 2018 Aug; 79(2):258-265.e4. PubMed ID: 29580859
[TBL] [Abstract][Full Text] [Related]
16. Metastatic melanoma to lymph nodes in patients with unknown primary sites.
Cormier JN; Xing Y; Feng L; Huang X; Davidson L; Gershenwald JE; Lee JE; Mansfield PF; Ross MI
Cancer; 2006 May; 106(9):2012-20. PubMed ID: 16568458
[TBL] [Abstract][Full Text] [Related]
17. Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas.
Egberts F; Bergner I; Krüger S; Haag J; Behrens HM; Hauschild A; Röcken C
Ann Oncol; 2014 Jan; 25(1):246-50. PubMed ID: 24276025
[TBL] [Abstract][Full Text] [Related]
18. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute.
Katz KA; Jonasch E; Hodi FS; Soiffer R; Kwitkiwski K; Sober AJ; Haluska FG
Melanoma Res; 2005 Feb; 15(1):77-82. PubMed ID: 15714125
[TBL] [Abstract][Full Text] [Related]
19. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.
Hsueh EC; DeBloom JR; Lee J; Sussman JJ; Covington KR; Middlebrook B; Johnson C; Cook RW; Slingluff CL; McMasters KM
J Hematol Oncol; 2017 Aug; 10(1):152. PubMed ID: 28851416
[TBL] [Abstract][Full Text] [Related]
20. Brain metastases in adult patients with melanoma of unknown primary in the Netherlands (2011-2020).
Padilla CS; Ho VKY; Mooijenkind TWAN; Louwman MWJ; de Vos FYFL; Bekkenk MW; Minnaard WA; Loef C; van Zanten SEMV
J Neurooncol; 2023 May; 163(1):239-248. PubMed ID: 37169949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
